Thursday, August 21, 2025 | 08:19 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Alembic, UCB in drug deal

Current Time 0:00
/
Duration Time 0:00
Progress: NaN%

Alembic, UCB in drug deal

<b>Alembic in licensing deal with UCB</b><br><br> Alembic has entered into a licensing agreement with Belgium-based UCB for its drug delivery platform for anti-epileptic drug Keppra XR (Levetiracetam extended release tablets).<br><br> According to an official release issued by Alembic to the BSE today, under the terms of the agreement, it would receive milestone payments of $11 million and royalty on future worldwide net sales of Keppra XR.

Other Videos

Explore News Home